The following article features coverage from the American Urological Association (AUA) 2019 meeting. Click here to read more of Renal & Urology News’ conference coverage.

CHICAGO—Metabolic syndrome (MetS) in men undergoing repeat prostate biopsy improves prostate cancer (PCa) detection, investigators reported at the 2019 American Urological Association annual meeting.

Cosimo De Nunzio, MD, of Ospedale Sant’Andrea, “La Sapienza” University, Rome, Italy, and colleagues studied 309 men with a median age of 68 years undergoing repeat 12-core biopsy for persistent clinical suspicion of PCa as a result of a PSA level of 4 ng/dL or higher, suspicious digital rectal examination findings, and more than 3 biopsy cores with high-grade prostatic intraepithelial neoplasia (HGPIN).

The study population included 109 men with MetS and 200 men without it. Compared with the no-MetS group, men with MetS were significantly older (70 vs 67 years) and had a significantly higher body mass index (29 vs 26 kg/m2), Dr De Nunzio’s team reported in a poster presentation. On second biopsy, a significantly greater proportion of men with MetS than without it were diagnosed with PCa (38% vs 27%).

On multivariate analysis, MetS was independently associated with significant 1.6-fold increased odds of a PCa diagnosis overall and 3.3-fold increased odds of Gleason score 7 or higher PCa on second biopsy.

“Our model if validated could be used to reduce the number of unnecessary biops[ies] in patients with a previous negative biopsy,” the authors concluded.

Read more of Renal & Urology News’ coverage of the AUA 2019 meeting by visiting the conference page.

Reference

De Nunzio C, Cancrini F, Cicione A, et al. Metabolic syndrome evaluation improves prostate cancer detection in patients undergoing a repeat biopsy. Presented at the 2019 American Urological Association annual meeting held May 3-6 in Chicago. Abstract MP18-05.